Peter S. Hammerman
0009-0006-9143-899X
Publication & Citation Trends
Publications
0 total
Expressed barcoding enables high resolution tracking of the evolution of drug tolerance.
Cited by 8
Semantic Scholar
Abstract 4026: JDQ443, a covalent inhibitor of KRASG12C with a novel binding mode, shows broad antitumor activity in KRASG12C preclinical models as a single agent and in combination with inhibitors of SHP2, MEK or CDK4/6
Cited by 3
Semantic Scholar
Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment OA
Cited by 43
Semantic Scholar
ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer OA
Cited by 107
Semantic Scholar
Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis OA
Cited by 63
Semantic Scholar
Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling OA
Cited by 115
Semantic Scholar
Abstract LB-122: Combinations of SHP2 inhibitor to overcome RAS activation by receptor tyrosine kinases in response to ERK inhibition
Cited by 0
Semantic Scholar
Abstract A44: SHP2 inhibition overcomes RTK-mediated pathway reactivation in KRAS-mutant tumors treated with MEK inhibitors
Cited by 1
Semantic Scholar
Research Topics
RNA modifications and cancer
(124)
Lung Cancer Treatments and Mutations
(115)
Fibroblast Growth Factor Research
(100)
Melanoma and MAPK Pathways
(75)
Cancer Immunotherapy and Biomarkers
(64)
Affiliations
Broad Institute
University of North Carolina at Chapel Hill
Brigham and Women's Hospital
Novartis (Switzerland)
American Institutes for Research